Table 3 Therapeutic strategies targeting invadopodia regulatory
From: Invadopodia in cancer metastasis: dynamics, regulation, and targeted therapies
Molecular target | Representative Drug(s) | Related pathway | Putative impact on invadopodia |
|---|---|---|---|
ABL2 | imatinib, nilotinib, dasatinib | TGFβ1/Smad signaling pathway | Inhibition of invadopodia maturation [196] |
AKT2 | triciribine | PI3 K/AKT2 signaling pathway | Inhibition of invadopodia formation [132] |
BRAF | sorafenib, vemurafenib, dabrafenib | Ca2 +/CAM-PYK2 signaling pathway | Inhibition of invadopodia formation [197] |
CXCL12 | NOX-A12 | Jak/Vav/Rho GTPase signaling pathway | Inhibition of MMP activity in invadopodia [198] |
CXCR4 | POL6326, BL-8040, burixafor | SDF1α/CXCR4 signaling pathway | Inhibition of MMP-mediated stimulation of invadopodia [100] |
EGFR | cetuximab, erlotinib, panitumumab, tesevatinib, nimotuzumab | EGFR-Src-Arg-cortactin signaling pathway | Inhibition of invadopodia maturation [106] |
ERBB2 | trastuzumab, varlitinib, tesevatinib, afatinib, pertuzumab, | Tyrosine kinases signaling pathway | Inhibition of MMP trafficking to invadopodia [148] |
ITGB3 | abciximab, cilengitide | Fak and Src signaling pathway | Inhibition of invadopodia formation, maturation, and MMP activation [199] |
KRAS | AZD4785 | Ral effector signaling pathway | Inhibition of invadopodia formation [200] |
MAPK1 | MAP kinase1 inhibitor, binimetinib, ulixertinib | K-Ras/MAPK/ERK2/MMP signaling pathway | Inhibition of MMP transcription, protein abundance, and enzymatic activity [201] |
MAPK8 | aplidine | MAPK signaling pathway | Inhibition of invadopodia formation [202] |
MET | crizotinib, tivantinib, cabozantinib, amuvatinib | c-Met/LanCL2/STAT3/Cortactin signaling pathway | Inhibition of invadopodia formation [203] |
MTOR | ridaforolimus, dactolisib, vistusertib, apitolisib | PI3 K/Akt/mTOR signaling pathway | Inhibition of invadopodia formation and matrix degradation [204] |
MMP14 | rebimastat, marimastat, prinomastat | ARL4 C-IQGAP1-MMP14 signaling pathway | Inhibition of invadopodia maturation and matrix degradation [205] |
NFKB1 | triflusal, thalidomide | NF-kB signaling pathway | Inhibition of invadopodia formation [206] |
NOTCH1 | OMP-52M51 | Notch1/Mena INV signaling pathway | Inhibition of invadopodia formation [44] |
PDGFR | dasatinib, sunitinib, pazopanib, axitinib, tivozanib | PDGFRα-La/SSB-LAMB1 signaling pathway | Inhibition of invadopodia formation [207] |
PDK1 | dichloroacetic acid | PDK1-AKT signaling pathway | Inhibition of invadopodia formation [156] |
PIK3 CA | dactolisib, pictilisib, buparlisib | PI3 K-AKT signaling pathway | Inhibition of invadopodia formation [208] |
SRC | dasatinib, saracatinib, nintedanib | EGFR-Src-Arg-cortactin signaling pathway | Inhibition of invadopodia formation and maturation [106] |
STAT3 | OPB-31121 | STAT3/Cortactin signaling pathway | Inhibition of invadopodia formation [203] |
TGFB1 | dalantercept | ERK signaling pathway | Inhibition of invadopodia formation [209] |